Clinical Trial

A Study of YL202 in Patients With Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-23.
Status change: Not Yet Recruiting → Recruiting 2026-03-05
Trial Details
NCT Number NCT07202364
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
Enrollment 100 participants
Start Date 2025-08-04
Primary Completion 2026-08-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-09